Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | JUN | P05412 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.54 |
| ▸ | CYP1A1 | P04798 | 6/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.53 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.53 |
| ▸ | TTR | P02766 | 1/20 | 0.52 |
| ▸ | DPP4 | P27487 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL533790 | 1.00 | RAB9A (0.61) | RAB9ANPC1MAPTKDM4EJUN | |
| SCHEMBL30930826 | 1.00 | RAB9A (0.61) | RAB9ANPC1MAPTKDM4EJUN | |
| SCHEMBL30012000 | 1.00 | RAB9A (0.61) | RAB9ANPC1MAPTKDM4EJUN | |
| SCHEMBL13957158 | 1.00 | RAB9A (0.61) | RAB9ANPC1MAPTKDM4EJUN | |
| SCHEMBL5962608 | 0.90 | RAB9A (0.53) | RAB9ANPC1MAPTKDM4EJUN | |
| SCHEMBL5962606 | 0.90 | RAB9A (0.53) | RAB9ANPC1MAPTKDM4EJUN | |
| SCHEMBL4621246 | 0.86 | L3MBTL1 (0.57) | RAB9ANPC1MAPTKDM4EJUN | |
| SCHEMBL4621254 | 0.86 | L3MBTL1 (0.57) | RAB9ANPC1MAPTKDM4EJUN | |
| SCHEMBL21959852 | 0.85 | TTR (0.51) | RAB9ANPC1MAPTKDM4EJUN | |
| SCHEMBL8133474 | 0.84 | MAPT (0.47) | RAB9ANPC1MAPTKDM4EJUN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119708027-A | Method for preparing boronated carbonyl derivative | 中国科学院大连化学物理研究所 | 2025-03-28 | — | — | CN | claimed |
| US-11993595-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-05-28 | — | — | US | disclosed |
| US-20230052191-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2023-02-16 | — | — | US | disclosed |
| US-11472798-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2022-10-18 | — | — | US | disclosed |
| CN-107674013-B | Polycyclic compound, preparation method, pharmaceutical composition and application thereof | 上海迪诺医药科技有限公司 | 2022-05-24 | — | — | CN | disclosed |
| EP-3828179-A1 | CYANOPYRROLIDINES AS DUB MODULATORS | Mission Therapeutics Limited (GB) | 2021-06-02 | — | — | EP | disclosed |
| US-20200369658-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2020-11-26 | — | — | US | disclosed |
| US-10774078-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2020-09-15 | — | — | US | disclosed |
| CN-111592534-A | Novel compounds | 特殊治疗有限公司 | 2020-08-28 | — | — | CN | disclosed |
| EP-3197883-B1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2020-03-18 | — | — | EP | disclosed |
| US-5378727-A | ADMINISTERING TO MAMMALS | G. D. SEARLE & CO. (US) | 1995-01-03 | — | — | US | disclosed |
| EP-0630366-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS PLATELET AGGREGATION INHIBITORS | G.D. Searle & Co. (US) | 1994-12-28 | — | — | EP | disclosed |
| US-5371096-A | (3-pyridyl)tetrafuran-2-yl substituted carboxylic acids | CIBA-GEIGY CORPORATION (US) | 1994-12-06 | — | — | US | disclosed |
| US-5254573-A | Substituted heterocyclic derivatives useful as platelet aggregation inhibitors | MONSANTO COMPANY (US) | 1993-10-19 | — | — | US | disclosed |
| EP-0284395-B1 | NOVEL GLYCEROL DERIVATIVE AND ANTI-HYPERTENSIVE AGENT | NIPPON CHEMIPHAR CO., LTD. (JP) | 1993-06-23 | — | — | EP | disclosed |
| WO-1993008164-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS PLATELET AGGREGATION INHIBITORS | G.D. SEARLE & CO. (US) | 1993-04-29 | — | — | WO | disclosed |
| EP-0539343-A1 | Substituted heterocyclic derivatives useful as platelet aggregation inhibitors | MONSANTO COMPANY (US) | 1993-04-28 | — | — | EP | disclosed |
| US-5183811-A | Glycerol derivative and anti-hypertensive agent | NIPPON CHEMIPHAR CO., LTD. (JP) | 1993-02-02 | — | — | US | disclosed |
| US-4962096-A | WITH REDUCED PLATELET AGGREGATING ACTION | NIPPON CHEMIPHAR CO., LTD. (JP) | 1990-10-09 | — | — | US | disclosed |
| EP-0284395-A2 | Novel glycerol derivative and anti-hypertensive agent | NIPPON CHEMIPHAR CO., LTD. (JP) | 1988-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774078-B2 | Compounds | UCHL1, UCHL3, UCHL5 | RAB9A 519/4885NPC1 2436/4885MAPT 2227/4885 |
| US-11472798-B2 | Compounds | UCHL1, UCHL3, UCHL5 | RAB9A 519/4885NPC1 2436/4885MAPT 2227/4885 |
| US-11993595-B2 | Compounds | UCHL1, UCHL3, UCHL5 | RAB9A 519/4885NPC1 2436/4885MAPT 2227/4885 |
| US-20200369658-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | RAB9A 480/4885NPC1 2546/4885MAPT 2428/4885 |
| US-20230052191-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | RAB9A 480/4885NPC1 2546/4885MAPT 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.